Table 1 Differential expression of p53, pRB, p21, p27, and number of altered biomarkers in subjects with and without urothelial cell carcinoma of the bladder
Individual biomarkers | Number of altered biomarkers | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
No. of patients | Altered p53 | Altered pRB | Altered p21 | Altered p27 | None | One | Two | Three | Four | |
Normal urothelium from subjects without bladder TCC | 9 | 0 | 0 | 0 | 0 | 9 | 0 | 0 | 0 | |
TURBT specimens from subjects with Ta, Tis, and/or T1 TCC | 74 | 25 (34%) | 29 (39%) | 26 (35%) | 35 (47%) | 16 (21.6) | 23 (31%) | 15 (20%) | 17 (23%) | 3 (4%) |
Cystectomy specimens from subjects treated with radical cystectomy | ||||||||||
Primary, index TCC | 226 | 120 (53%) | 112 (50%) | 76 (34%) | 136 (60%) | 28 (12%) | 56 (25%) | 59 (26%) | 62 (27%) | 21 (9%) |
Histologically normal urothelium adjacent to primary TCC | 72 | 11 (15%) | 16 (22%) | 16 (22%) | 19 (26%) | 25 (35%) | 34 (47%) | 11 (15%) | 2 (3%) | 0 (0%) |
Concomitant carcinoma in situ areas | 40 | 18 (45%) | 17 (43%) | 14 (35%) | 21 (53%) | 4 (10%) | 14 (35%) | 14 (35%) | 6 (15%) | 2 (5%) |
Metastatic lymphoid tissue from subjects treated with radical cystectomy | 50 | 38 (76%) | 34 (68%) | 23 (46%) | 32 (64%) | 1 (2%) | 8 (16%) | 12 (24%) | 21 (42%) | 8 (16%) |
